Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review

Dec 18 2012

• By Bridget Silverman

Related Content

Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain

Mar 01 2011

The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible

Mar 01 2011

FDA Approves <em>Zytiga</em> In Earlier Prostate Cancer Setting

Dec 11 2012

Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC

Dec 18 2012

Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote

Jun 01 2010

Related Companies

Medivation, Inc.

Astellas Pharma, Inc.

Johnson & Johnson

Sanofi

Dendreon Corporation

Sanofi

Novartis AG

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Clinical Trials Regulation Approvals BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window